Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lakshmi Rajdev

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Journal of Cellular Signaling|July 2, 2020
COVID-19 Clinical ResearchJeffrey Chi, David Chitty, Meeyoung Lee, et al.
Journal of Gastrointestinal Cancer|November 3, 2019
The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic CancerMichael Shusterman, Erin Jou, Andreas Kaubisch, et al.
Clinical Breast Cancer|March 17, 2004
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancerJoshua P Raff, Lakshmi Rajdev, Umekalsoom Malik, et al.
Clinical Colorectal Cancer|January 31, 2012
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancerArjun Sood, Danielle McClain, Radhashree Maitra, et al.
Investigational New Drugs|October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Investigational New Drugs|October 14, 2018
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trialsAudrey E Kam, Gopichand Pendurti, Umang H Shah, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignanciesSanjay Goel, Minaxi Jhawer, Lakshmi Rajdev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium TrialJoseph A Sparano, Jeannette Y Lee, Joel Palefsky, et al.
Clinical Colorectal Cancer|April 17, 2017
Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal CancerSanjay Goel, Abdissa Negassa, Ashish Khot, et al.
Eclinicalmedicine|December 25, 2024
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome setRobert Samuel, Stephen R Knight, Richard Adams, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Cellular Signaling|July 2, 2020
COVID-19 Clinical ResearchJeffrey Chi, David Chitty, Meeyoung Lee, et al.
Journal of Gastrointestinal Cancer|November 3, 2019
The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic CancerMichael Shusterman, Erin Jou, Andreas Kaubisch, et al.
Clinical Breast Cancer|March 17, 2004
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancerJoshua P Raff, Lakshmi Rajdev, Umekalsoom Malik, et al.
Clinical Colorectal Cancer|January 31, 2012
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancerArjun Sood, Danielle McClain, Radhashree Maitra, et al.
Investigational New Drugs|October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Investigational New Drugs|October 14, 2018
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trialsAudrey E Kam, Gopichand Pendurti, Umang H Shah, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignanciesSanjay Goel, Minaxi Jhawer, Lakshmi Rajdev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium TrialJoseph A Sparano, Jeannette Y Lee, Joel Palefsky, et al.
Clinical Colorectal Cancer|April 17, 2017
Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal CancerSanjay Goel, Abdissa Negassa, Ashish Khot, et al.
Eclinicalmedicine|December 25, 2024
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome setRobert Samuel, Stephen R Knight, Richard Adams, et al.
Pageof 5